Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 33,009 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo/placebo Clear all
Terminated Phase 4 Interventional Results available

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

NCT03988842
View directory record Official record
Conditions
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Alteplase, Unfractionated heparin, Placebo, Apixaban
Drug
Lead sponsor
Victor Tapson, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Study of Weight Loss Using Gastric Stimulation in Obese Patients

NCT00200083
View directory record Official record
Conditions
Obesity, Morbid Obesity
Interventions
Transcend II Model 8848
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Gainsville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

NCT05955183
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

NCT04906694
View directory record Official record
Conditions
Covid19
Interventions
COVI-DROPS, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Colorado Springs, Colorado • Jacksonville, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

NCT00115622
View directory record Official record
Conditions
Hayfever, Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Interventions
fluticasone furoate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

NCT02070302
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Benjamin Sucher
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Duration of Skin Numbing Effect Created by the S-Caine™ Peel

NCT00110253
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional

Impact of Bright Light Therapy on Prader-Willi Syndrome

NCT05939453
View directory record Official record
Conditions
Prader-Willi Syndrome, Excessive Daytime Sleepiness, Hyperphagia, Body Weight, Mood, Behavior
Interventions
Sham Light, Bright Light Therapy
Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 88 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00130845
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations.

NCT06219161
View directory record Official record
Conditions
Stem Cells
Interventions
NAD3
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
40 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 5, 2026, 5:46 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Ciprofloxacin in Humans

NCT00964561
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug · Other
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973
View directory record Official record
Conditions
Overweight , Obesity, Adults
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Tempe, Arizona • Oceanside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Terminated Phase 3 Interventional Results available

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
View directory record Official record
Conditions
Covid-19
Interventions
CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Chula Vista, California • El Centro, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

NCT01953341
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

NCT04283656
View directory record Official record
Conditions
Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions
Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Early Phase 1 Interventional

Methamphetamine and Troriluzole

NCT06989853
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Placebo, Methamphetamine
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Bay98-7196, Dose Finding / POC Study

NCT02203331
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402
View directory record Official record
Conditions
Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions
Barzolvolimab, Matching Placebo
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry

NCT01971853
View directory record Official record
Conditions
Pain
Interventions
oral placebo, Oral Analgesics
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 8 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-791325, Moxifloxacin, Placebo matching BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 5, 2026, 5:46 AM EDT
Active, not recruiting Phase 2 Interventional

Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

NCT04800159
View directory record Official record
Conditions
HIV, Cannabis Use
Interventions
THC Cannabis, CBD Cannabis, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 5, 2026, 5:46 AM EDT